APOB and fatty liver disease: Interestingly, previous association studies did not identify the PPARA gene as genome-wide significant, even though PPARA significantly contributes to the h2RV of ApoB and that both PPARA and APOB are involved in several lipid-related pathways (Supplementary Data 5), fatty liver disease, and dyslipidemias (Fig. 6), and identified as “druggable genome” in the DGIdb database (Supplementary Data 3).